Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan(Mount Vernon Hospital), Sophie Piperno‐Neumann(Institut Curie), Marcus O. Butler(University of Toronto), Ryan J. Sullivan(Dana-Farber Cancer Institute), Lev Demidov(Heidelberg University), Josep M. Piulats(Institut Català d'Ornitologia), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Omid Hamid(Cedars-Sinai Medical Center), Brendan D. Curti(Providence Portland Medical Center), Sebastian Ochsenreither(Heidelberg University), Marlana Orloff(Heidelberg University), Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center), Max Schlaak(Charité - Universitätsmedizin Berlin), Cornelia Mauch(University Hospital Cologne), Jessica C. Hassel(German Cancer Research Center), Melinda Yushak(Emory University), Lauris Gastaud(Heidelberg University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Joseph J. Sacco(University of Liverpool), Howard Goodall(Heidelberg University), Anthony M. Joshua(St Vincent's Hospital Sydney), Richard D. Carvajal(Northwell Health), Reinhard Dummer(University Hospital of Zurich), Mohammed Milhem(University of Iowa), April K.S. Salama(Duke University), Chris Holland(Amgen (United States)), Shaad E. Abdullah(Heidelberg University), John M. Kirkwood(UPMC Hillman Cancer Center)
Cited by 869
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k